Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
94.57
-0.04 (-0.04%)
Nov 21, 2024, 11:04 AM EST - Market open
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 124.93, with a low estimate of 105 and a high estimate of 180. The average target predicts an increase of 32.11% from the current stock price of 94.57.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AXSM stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 8 | 8 | 8 | 8 |
| Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $112 → $116 | Buy | Maintains | $112 → $116 | +22.67% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $130 | Strong Buy | Reiterates | $130 | +37.47% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $130 | Strong Buy | Reiterates | $130 | +37.47% | Nov 12, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $130 → $131 | Buy | Maintains | $130 → $131 | +38.53% | Oct 4, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +13.15% | Sep 20, 2024 |
Financial Forecast
Revenue This Year
380.64M
from 270.60M
Increased by 40.67%
Revenue Next Year
644.30M
from 380.64M
Increased by 69.27%
EPS This Year
-5.82
from -5.27
EPS Next Year
-2.21
from -5.82
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 410.0M | 791.1M | 1.8B | ||
| Avg | 380.6M | 644.3M | 1.1B | ||
| Low | 352.2M | 460.4M | 846.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 51.5% | 107.8% | 171.9% | ||
| Avg | 40.7% | 69.3% | 73.7% | ||
| Low | 30.1% | 20.9% | 31.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.68 | 1.21 | 10.03 | ||
| Avg | -5.82 | -2.21 | 4.47 | ||
| Low | -6.90 | -4.95 | -2.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.